Journal article
Immunomodulatory Treatments in Epilepsy
Seminars in pediatric neurology, v 21(3), pp 232-237
01 Sep 2014
PMID: 25510946
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The role of immunity and inflammation appears to be an integral part of the pathogenic processes associated with some seizures, particularly with refractory epilepsy. Prompt treatment with immunotherapy may lead to better outcomes. Immune treatment options for treatment of epilepsy include therapies such as corticosteroids, immunoglobulins, plasmapheresis, or steroid-sparing drugs such as azathioprine. Recent alternatives have included even more aggressive treatment with cyclophosphamide, anti-pre-B-lymphocyte monoclonal antibody rituximab, and monoclonal antibodies such as efalizumab or natalizumab, which are presently used for other inflammatory disorders. Randomized controlled trials of immunotherapy in presumed autoimmune epilepsy are needed to provide further support for the rapid use of immunotherapy in patients with immune mediated epilepsy. (C) 2014 Elsevier Inc. All rights reserved.
Metrics
Details
- Title
- Immunomodulatory Treatments in Epilepsy
- Creators
- Joseph J. Melvin - St. Christopher's Hospital for ChildrenH. Huntley Hardison - St. Christopher's Hospital for Children
- Publication Details
- Seminars in pediatric neurology, v 21(3), pp 232-237
- Publisher
- Elsevier
- Number of pages
- 6
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:000346888000007
- Scopus ID
- 2-s2.0-84916877125
- Other Identifier
- 991019168070504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Clinical Neurology
- Pediatrics